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ABSTRACT 
ROLE OF PERIPROSTATIC ADIPOSE TISSUE IN PROSTATE 
CANCER CELLS 
 
by 
 
Massa Mafi 
 
 
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Professor Jennifer A. Doll 
 
 
 Background: Prostate cancer (PCa) is a leading men’s health concern. It is the 
most common cancer diagnosed in American men. Obesity, especially excess visceral 
adipose tissue, increases the risk of PCa progression; however, the mechanism is yet 
unknown.  In addition, studies have demonstrated that the locale of the visceral adipose 
depots affects its function and change the levels of secreted products.  In PCa patients, 
increased thickness of the periprostatic adipose tissue (PPA), a type of visceral adipose 
tissue which covers the prostate organ, is positively correlated with progression, 
suggesting that this depot may specifically stimulate PCa progression in obese patients. 
In this study, I tested the hypothesis that visceral adipose tissue (VAT) secretions, and 
specifically PPA tissue secretions, from a mouse model will induce pro-proliferative 
activity of microvascular endothelial and PCa cells. This hypothesis was tested by two 
aims. The first was quantifying the pro-proliferative activity of subcutaneous (SQA) and 
VAT secretions on normal human endothelial cells. The second aim was to measure the 
pro-proliferative activity of adipose tissue secretions on PC-3 PCa cells. 
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Method: SQA and two types of VAT, including visceral fat pad (VFP), and PPA tissues 
from wildtype mice C57BI/6 and obese mice were collected. Tissues were minced and 
placed in explant cultures in serum-free media. Conditioned media (CM) was collected 
after 48 hours of incubation. Human microvascular endothelial cells (HMVEC) were 
treated with concentrated CM of each adipose tissue depot. HMVEC and PC-3 cells were 
also treated with unconcentrated CM of each adipose depot. The proliferative activity and 
total protein concentration of each adipose tissue sample was analyzed via MTT 
proliferation and protein quantification assay, respectively. Data from the MTT assay 
were analyzed by normalizing them to total protein concentration per gram weight of 
each adipose tissue sample. Lipolytic activity of each adipose tissue sample was also 
measured by performing a free glycerol assay. 
Result: With HMVEC cells, the unconcentrated 100% VAT CM treatment group had  
significantly higher cell numbers  as compared to the SQA 100% CM or negative control 
groups (P-value < 0.001). However, when the CM was concentrated no HMVEC 
proliferation was observed with any adipose tissue types that were tested. The 30% 
diluted SQA tissue CM also significantly induced proliferation of PC-3 PCa cells (P-
value ≤ 0.05) as compared to the negative control. However, no proliferation was seen 
when a larger sample size was used. Finally, a significant increase in PC-3 PCa cell 
proliferation was observed with PPA tissue CM treatment when data was normalized to 
total protein concentration per gram weight of each sample (P-value < 0.001 vs. the 
negative control). There was also no detectable difference in lipolytic activity between 
the SQA, VAT, or PPA tissues. 
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Conclusion: My results demonstrated that treatment with the PPA tissue secretions 
increased PC-3 cell number over that of either the VFP or the SQA tissue secretions. 
These data suggest that unique characteristics of the PPA tissue may contribute to PCa 
progression. 
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INTRODUCTION 
The Prostate and Prostate cancer 
 The prostate is a walnut-sized gland that constitutes a part of the male 
reproductive system. The prostate is located under the bladder and in front of the rectum. 
The main function of the prostate is to secrete some of the fluid content of semen (CDC, 
2013). Family history, older age, and genetic background can increase the likelihood of 
developing prostate cancer (PCa) (Hsing et al., 2007). PCa is a leading men’s health 
concern. It is the second-most common cancer diagnosed in American men (CDC, 
2013a). According to the Centers for Disease Control and Prevention (CDC), PCa is 
more common among men older than 65, but the chance of developing PCa increases 
after age 50 (CDC, 2014). It has been estimated that 238,590 men are diagnosed with 
PCa and 29,270 men among these patients die from the disease in America annually 
(Siegel et al., 2013). Genetics, race, and advanced age are the most common risk factors 
that are involved with developing PCa, as well as lifestyle factors such as a high fat diet 
(CDC, 2002). A study by Xue et al. showed that feeding a Western-style diet (low 
calcium and vitamin D, but high in fat content) to C57BL/6J mice for 5 and 16 weeks 
increased the proliferation of prostate epithelial cells in the anterior and dorsolateral lobes 
of the mouse prostate, but not in ventral lobe of the prostate (Xue et al., 1997). Low grade 
PCa is a slow-growing cancer (CDC, 2013); hence, men are usually diagnosed when they 
are old and/or they might die from other diseases without even being diagnosed with PCa 
(CDC, 2013b). However, high-grade PCa which also affects younger men (Roach et al., 
1999) tends to grow quickly (Gleason 1992). The rate of dying from the disease is also 
3% higher in young patients than in older patients (Lin et al., 2009).   
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Digital rectal exam (DRE) and the prostate specific antigen (PSA) test are the two 
common screening tests that are available for PCa detection (CDC, 2013c). In a DRE, a 
doctor can physically check the prostate by inserting his finger into the patient’s rectum 
and examine any abnormalities (CDC, 2013c) such as presence of nodules (Simmons et 
al., 2011). In PSA testing, elevated levels of PSA in the blood can indicate the presence 
of PCa (CDC, 2013c). A PSA level of above 2.5-4 ng/mL is considered to be abnormal 
and it is linked to an increased chance of having PCa. Some factors, including enlarged 
prostate or inflammation (Nadler et al., 1995), age, race, infection, and certain 
medications (CDC, 2013c), can increase the level of PSA in non-prostate cancer men; 
thus, the PSA test alone cannot be used to diagnose PCa. Therefore, further follow-up 
screening and biopsy is needed to confirm the presence of the tumor (Simmons et al., 
2011). A high PSA level is correlated with a higher grade (Gleason score) PCa, meaning 
that men with higher PSA levels have more aggressive PCa (Shih et al., 1992; Thompson 
et al., 2004).  
 
The Gleason score is a system used for PCa pathological grading (Andren et al., 2006; 
Gleason, 1992). This technique indicates the survival rate based on the histology of the 
cancer tissue (Andren et al., 2006; Gleason, 1992). In this technique, the primary and the 
secondary patterns, which are the most and second most common patterns of cancer 
tissue in the prostate, are assigned a grade ranging from one to five. The sum of these two 
grades makes a range of two to ten, which is called the Gleason score. A score of six is 
considered to be cancer, and a score of seven or above represents a more aggressive 
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tumor (Witte et al., 2000). D’Amico introduced a classification method to aid in the 
identification of more aggressive PCa. In the D’Amico classification method, the 
combination of the Gleason score, the PSA level, and the size of the tumor were used to 
predict the risk of PCa recurrence (D'Amico et al., 1998; Kane et al., 2005).  
Obesity in Prostate Cancer 
Obesity, the prevalence of which is rapidly growing in the United States, is known to be 
associated with aggressive PCa, which tipically leads to death (Freedland and Aronson, 
2005; Freedland et al., 2009; Hsing et al., 2007). Obesity is defined as a body mass index 
(BMI) of greater than or equal to 30 (Buschemeyer and Freedland, 2007). The majority of 
PCa studies examining the relationship with obesity have used BMI and/or waist to hip 
ratio for evaluating the amount of adipose tissue in the body (Buschemeyer and 
Freedland, 2007). Although these methods cannot differentiate between types of adipose 
tissues or their locations in body, they are reasonable methods to measure overall 
adiposity (Hsing et al., 2007; Pouliot et al., 1994). Supporting this, increased BMI 
correlates with more aggressive PCa (Baillargeon and Rose, 2006; Kane et al., 2005).  In 
a study by Kane et al., 2,952 normal weight, overweight, and obese PCa patients and PCa 
survivors participated. They were classified based on low to high risk PCa using 
D’Amico classification and the PSA level that was measured. The study then compared 
the groups based on BMI and demographics such as age, ethnicity, education, income, 
relationship status, smoking, alcohol, and comorbidities using univariate and multivariate 
analysis. The result indicated that normal and even overweight patients are at low risk, 
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while obese patients are at high risk, for high-grade PCa (Kane et al., 2005).  A review of 
large prospective cohort studies by Freedland and Aronson, which monitored healthy 
men for 13 to 16 years for medical problems such as obesity and cancer, demonstrated 
that the rate of dying from PCa increases as the BMI increases (Freedland and Aronson, 
2005). For example one of these studies showed that 20% of obese men with a BMI of 
30.0-34.9 kg/m2 died from PCa, while the rate of death from PCa was 14% more among 
even more obese men with a BMI of 35.0-39.9 kg/m2 (Freedland and Aronson, 2005). 
Some research also suggests that obesity is also a risk factor for PCa, but because of the 
complex association, the exact mechanism that is involved is not known yet (Baillargeon 
and Rose, 2006).  
 
A high fat diet often leads to obesity, and obesity plays an important role in increasing 
the risk of developing many cancers, such as colon, gallbladder, kidney, and pancreatic 
cancer (Hsing et al., 2007). While in PCa, where risk is still being studied, it is well 
established that a high fat diet and obesity are correlated with more aggressive disease. 
Excess body fat is associated with altered metabolism, which may contribute to cancer 
progression (Hsing et al., 2007). More than one-third of adults in the United States are 
obese (CDC, 2013d); therefore, understanding the interaction between obesity and PCa is 
important.  
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Adipose tissue depots 
There are two types of adipose tissue in mammals’ bodies, white and brown (Gustafson, 
2010). White adipose tissue is made up of adipocytes, which are responsible for storing 
excess energy as lipids (Fonseca-Alaniz et al., 2007). White adipose tissue can be 
generalized by its location as subcutaneous adipose (SQA) tissue, located beneath the 
skin, or visceral adipose tissue (VAT), which covers the organs (Fain et al., 2004). These 
adipose tissues consist of adipocytes, fibroblasts, macrophages and some other stromal-
vascular fraction cells. Macrophages and fibroblasts constitute about one-half of the total 
cell number (Hausman, 1985).  
 
Adipose tissue depots differ in their production of cytokines and adipokines that are 
involved in autocrine, paracrine, and endocrine systems in the body (Greenberg and 
Obin, 2006; Tritos and Mantzoros, 1997). Some fat depots are more associated with the 
incidence or progression of some diseases than other fat depots (Bjorndal et al., 2011). 
For example, excess visceral adipose tissue in the body is linked to many diseases, such 
as cardiovascular and type 2-diabetes (Hajer et al., 2008). Hence, the differences between 
SQA tissue and VAT are not only limited to their location, but also vary in function and 
metabolism (Fonseca-Alaniz et al., 2007).  Excess visceral adipose tissue in men is 
strongly related with some type of cancers, including colon, esophagus, gallbladder, 
kidney, pancreas, rectum, and thyroid (Murphy 2013), and it increases the risk of high-
grade PCa (Gong et al., 2006). 
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It is now recognized that adipose tissue is an endocrine organ because it produces some 
hormones and cytokines such as leptin, interleukin-6 (IL-6), and tumor necrosis factor - α 
(TNF-α) (Ahima and Flier, 2000; Fain et al., 2004; Fruhbeck et al., 2001). IL-6 is a key 
regulator in immune system. It also plays a role in lipolytic activity and maintains body 
weight (Hoene and Weigert, 2008). TNF-α is one of the main mediators of inflammation 
(Kern et al., 2001; Suganami et al., 2005), and leptin is a hormone that controls appetite 
and regulates energy expenditure to maintain body weight homeostasis (Benoit et al., 
2004; Saglam et al., 2003). Adipose tissue’s endocrine function can be altered by excess 
body adipose tissue. The adipose tissue in obese individuals has different levels of 
adipokine production, lipid metabolism, and adipocyte differentiation (Kershaw and 
Flier, 2004). This is mostly related to individuals’ age, sex, nutrition, and also the ability 
to maintaining energy balance by the body’s adipose tissues (Bjorndal et al., 2011; 
Wajchenberg, 2000).  
 
The periprostatic adipose (PPA) tissue, which covers the prostate organ, is one type of 
visceral adipose tissue. Some studies link excess PPA tissue to aggressive PCa.  PPA 
tissue thickness increases in obesity, and a clinical study by Bhindi et al. has shown that 
patients with thicker PPA tissue have more aggressive PCa (Bhindi et al., 2012). They 
indicated that measuring the PPA tissue thickness via transrectal ultrasonography can be 
a stronger predictor for aggressive PCa than overall obesity (Bhindi et al., 2012). Another 
study has shown that high levels of IL-6 are secreted from the PPA tissue of patients with 
a high grade of PCa (Finley et al., 2009). However, the molecular mechanism that is 
involved and the unique characteristics of the PPA adipose tissue that promote this 
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activity are still unclear. A pilot study by Venkatasubramanian et al., the authors 
collected SQA and PPA tissue from lean, overweight, and obese PCa patients during 
prostate removal surgery. They found that PPA tissue secretions from obese PCa patients 
were more inductive in both endothelial and PC-3 PCa cells in an MTT proliferation 
assays than PPA secretions from lean or overweight men and SQA tissues, but lean PPA 
tissues were also inductive over the negative control (Venkatasubramanian et al., 2014). 
Therefore, PPA tissue seems to contribute to PCa progression.  
Obese versus lean adipose tissue 
White adipose tissue works as a thermal insulator to maintain body temperature 
(Fonseca-Alaniz et al., 2007). In a lean body, white adipose tissue, including SQA and 
visceral adipose tissue, can store 200,000- 300,000 kcal for energy. Adipose tissue also 
has an endocrine function and it secrete high levels of adipokines such as TNF-α, IL-6, 
and leptin. The functional role of these adipokines is diverse and induces regulating 
inflammation, cell growth, apoptosis, and motility (Toren et al., 2013; Wang et al., 2012). 
However, the secretion level of the adipokines is altered when adipose tissue deposition 
increases, as occurs with obesity. Adipose tissue can be expanded by both adipocyte cell 
number and size. Each fat cell has a capacity to store 0.7 to 0.8 µg of lipid. If more lipids 
are produced in the body, then more fat cells will be generated (Gustafson, 2010). 
Therefore, by increasing the number and size of the adipocytes in obesity, the expression 
level of some adipokines such as IL-6, TNF-α, and leptin from the adipocytes can also be 
elevated.  
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Although only 10% of the total body fat is composed of visceral adipose tissue, it has 
been shown to be metabolically more active than subcutaneous adipose tissue (Hsing et 
al., 2007). Visceral obesity has an influence on cellular pathways and alters hormone 
circulations (Mistry et al., 2007).  The effect of VAT on cellular pathways could be either 
local through autocrine and paracrine mechanisms or via endocrine pathways mechanism. 
It could also be related to the metabolic and lipolytic activity of the VAT (Deveaud et al., 
2004; Wajchenberg, 2000; Yang et al., 2008). Alteration in androgen metabolism and 
insulin resistance (metabolic syndrome) are examples of these effects (Hsing et al., 2007; 
Mistry et al., 2007). Cytokine and hormones are the key regulators in these mechanisms; 
therefore, changes in the regulation and secretion level of each adipokine are associated 
with some health issues (Hsing et al., 2007; Mistry et al., 2007). Some adipokines 
expression is increased with obesity, and a subset of these is known to enhance the 
aggressiveness of PCa such as IL-6, leptin and TNF-α (Mistry et al., 2007).  
Angiogenesis and Obesity 
When adipose tissue expands in the body, the tissue must induce angiogenesis, the 
formation of new blood vessels from existing blood vessels.  The new blood vessels are 
required to transfer oxygen and nutrients to the growing adipose depot (Fried et al. 1998). 
Angiogenesis is also a required step for tumor growth and development (Folkman, 1992). 
In a normal tissue, there is a balance between pro-angiogenic factors and inhibitory 
factors; however, in tumor tissues, alterations in this equilibrium might lead to higher 
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production of pro-angiogenic factors and result in tumor growth (Kerbel, 2000). 
Furthermore, a high level of cytokines in the tumor microenvironment could modulate 
the expression of some growth factor molecules which enhance tumor growth (Wu, 
2012). For example, high levels of leptin cause proliferation of vascular endothelial cells 
in vitro and also initiates angiogenesis in vivo (Mistry et al., 2007). Other secreted factors 
from obese adipose tissue could also contribute to a net pro-angiogenic function. 
Leptin 
Circulating  leptin in a lean body not only functions to maintain energy balance and 
immune system function, but it also plays a role in growth and maintenance of 
reproductive tissues, such as prostate tissue (Considine et al., 1996; Mistry et al., 2007). 
Expression of leptin has been shown to be elevated with increasing total body adiposity.  
Average leptin serum levels in a normal weight body is about 4 ng/ml, while in an obese 
body, this level is 10 times higher (40 ng/ml) (Considine and Caro, 1996; Frankenberry et 
al., 2004). This elevation might be related to higher insulin levels, which do impact leptin 
production (Fantuzzi, 2005). High levels of leptin have been shown to induce vascular 
endothelial cell proliferation in vitro. For example, a vitro study by Frankenberry et al. 
demonstrated increased DU145 and PC-3 cell proliferation with increasing leptin levels 
(Frankenberry et al., 2004). They also observed higher migration activity in these PCa 
cells with increasing leptin levels (Frankenberry et al., 2004). Another study, by Onuma 
et al., also examined leptin-stimulated growth of different cell lines, including DU145, 
PC-3, and LNCaP-FGC. The results, indicated that leptin induces proliferation of 
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androgen-independent cells, DU145 and PC-3, but not androgen dependent cell line, 
LNCaP-FGC (Onuma et al., 2003).  
Interleukin-6 (IL-6) 
Plasma IL-6 levels have been shown to be positively correlated with obesity (Kern et al., 
2001). Moreover, a study by Fried et al. on obese human adipose tissues has shown that 
for the same number of adipocytes, IL-6 expression is three fold higher in omental VAT 
as compared to SQA tissue (Fain et al., 2004; Fried et al., 1998). Circulating IL-6 is 
positively associated with adipocyte size and a high BMI. The expression of IL-6 is also 
higher in VAT than SQA tissue (Gustafson, 2010). In an in vitro study by Chung et al., 
two androgen- independent PCa cell lines (DU-145 and PC-3) and two androgen-
dependent PCa cell line (LNCaP-ATCC and LNCaP-GW) were tested for cytokine 
production levels. The result from this study showed that the androgen-independent PCa 
cell lines express higher levels of IL-6 (Chung et al., 1999). In addition, an in vitro study 
by Okamoto et al. demonstrated that IL-6 has the ability to induce proliferation in PC-3 
and DU-145, via autocrine activity, while IL-6 inhibits LNCaP, via the paracrine system 
(Okamoto et al., 1997). 
Tumor Necrosis Alpha (TNF-α) 
TNF-α is another multifunctional adipokine that is produced by the macrophages in 
adipose tissues (Fonseca-Alaniz et al., 2007; Wisse, 2004). Similarly to leptin and IL-6, 
the expression of TNF-α is also increased by obesity (Fonseca-Alaniz et al., 2007). 
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Unlike the expression of IL-6 and leptin, which is mostly related to visceral obesity, 
increased TNF-α expression is related to overall obesity (Cartier et al., 2008). TNF-α has 
been shown to increase the production of leptin (Trayhurn and Beattie, 2001) and IL-6 
(Fonseca-Alaniz et al., 2007). An in vitro study by Gasparian et al., the authors showed 
that TNF-α can induce proliferation of androgen-independent PCa cells via activation of 
NF-ƙB which prevents cell apoptosis. In this case NF-ƙB promotes survival signaling, 
and therefore promotes PCa proliferation (Gasparian et al., 2002). The precise 
mechanism through which obese adipose tissue promotes PCa progression is still unclear, 
but theories include (1) alteration in adipokines and hormones such as estrogen, 
testosterone and androgen, (2) high levels of pro-inflammatory cytokines such as TNF-α, 
(4) through signaling mechanisms associated with insulin resistance, and/or (5) through 
increased dietary fat intake which alters free fatty acid levels and function (Mistry et al., 
2007).  
 
Several  in vitro studies have shown that, for the same weight of lean adipose tissue, SQA 
tissue produces more leptin, IL-6 (Wisse, 2004) and TNF- α (Fonseca-Alaniz et al., 2007; 
Fruhbeck, 2006; Steppan et al., 2001) as compared to  VAT. A recent study by Fjeldborg 
et al. comparing lean and obese human SQA tissue demonstrated that obese SQA tissue 
produces more IL-6 and TNF-α than lean SQA tissue (Fjeldborg, 2014). In a study by 
Fried et al., IL-6 expression was compared between omental VAT and SQA tissue of 10 
obese humans. The result from the explant cultures of the adipose tissue demonstrated 
that omental adipose tissue produces three times more IL-6 than SQA tissue (Fried et al., 
1998). The release of IL-6 was also higher from omental isolated adipocytes than SQA 
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isolated adipocytes; however, this secretion was only about 10% of the total IL-6 release 
from the omental tissue (Fried et al., 1998). Nevertheless, in the case of obesity, 
abdominal visceral adipose tissue, which typically makes up only 10% of the total body 
fat, is metabolically more active than subcutaneous fat (Hsing et al., 2007). In addition to 
the metabolic activity, the rate of lipolysis is also higher in VAT than SQA (Jensen, 
2006). Moreover, visceral adiposity is linked to many diseases, such as cardiovascular 
(Wajchenberg, 2000), insulin resistance, and type 2 diabetes (Virtanen et al., 2005). 
 
A study by Kern et al. also examined the level of TNF-α expression from both lean and 
obese human adipose tissue (Kern et al., 1995). The result revealed that TNF-α levels are 
elevated by obesity and the levels, can be decreased by weight loss (Kern et al., 1995). 
TNF-α also elevates the expression of other cytokines and hormones, such as IL-6 and 
leptin, by adipocytes (Greenberg and Obin, 2006; Kershaw and Flier, 2004; Margetic et 
al., 2002). Both IL-6 and TNF-α are secreted by infiltrating macrophages in adipose 
tissue and act as paracrine and / or autocrine factors (Gustafson, 2010; Hotamisligil et al., 
1995; Xu et al., 2002). They are also involved in accelerating lipolysis and the secretion 
of free fatty acids (FFA) (Gustafson, 2010; Sacca et al., 2012b). Therefore, dysregulated 
secretion of cytokines and hormones by visceral adipose tissue, due to obesity, may be 
involved in PCa progression (Hsing et al., 2007). More research is needed to identify the 
most relevant molecular factors and cellular mechanism that are involved in PCa 
progression process during VAT dysfunction. 
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A subtype of visceral adipose tissue, the periprostatic adipose (PPA) tissue, which 
surrounds the prostate organ, has been investigated for its role in PCa progression. In a 
study by Bhindi et al., PPA tissue thickness was measured via transrectal ultrasonography 
in 931 patients who underwent a prostate biopsy. This study showed that the thickness of 
PPA tissue was a better predictor for developing PCa or for delivering an aggressive form 
of the disease in patients than measures of overall obesity (Bhindi et al., 2012). 
Furthermore, a study by Finley et al., on PPA tissue taken from PCa patients, 
demonstrated that IL-6 is highly expressed by PPA tissue and that the levels positively 
correlate with increasing Gleason score of the cancer. Therefore, they suggest that the 
high concentration of IL-6 might contribute to PCa aggressiveness (Finley et al., 2009). 
Another study, by Sacca et al., compared the activity of secretions collected from PPA 
tissues from patients with PCa to patients with benign prostatic hyperplasia on 
proliferation, migration, adhesion, and metalloproteinase expression in two PCa cell 
lines, LNCap and PC-3 in vitro (Sacca et al., 2012a). Their results indicated that secretion 
of pro-metalloproteinases (pro-MMP) from PPA is higher from patients with PCa than in 
patients with benign prostate hyperplasia. MMP-9 is an endopeptidase that is involved in 
tumor growth and aggressiveness by cleaving molecules such as cytokines and growth 
factor (Chambers and Matrisian, 1997; Mira and Gómez-Moutón, 2004; Nelson et al., 
2000). MMP-9 is secreted as pro-MMP-9 which is then cleaved into an active enzyme 
(Wilcock et al., 2011). MMP-9 can induce the release of growth factors in addition to 
degrading the extracellular matrix; therefore, it creates an environment that maintains 
tumor growth and allows for invasion and metastasis (Bergers et al., 2000; Chakrabarti 
and Patel, 2005). In addition, MMP-9 expression and activity levels are directly related to 
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body adiposity (Bouloumie et al., 2001; Unal et al., 2010). Hence, understanding the role 
of factors secreted by the PPA tissue on PCa progression is crucial. Previous data have 
shown that the PPA from obese PCa patients is more pro-proliferative on PCa cells 
compared to lean PPA and lean or obese SQA tissue depots (Venkatasubramanian et al., 
2014).  Studies to date have not compared the effect of all these three adipose tissue 
secretions on human normal endothelial or PCa cells. The overarching hypothesis for this 
study is that VAT secretions, and specifically PPA tissue secretions, from a mouse model 
will induce pro-proliferative activity of microvascular endothelial and PCa cells.  
 
Specific Aim 1 
To quantify the pro-proliferative activity of subcutaneous (SQA) and visceral adipose 
tissue (VAT) secretions on normal human endothelial cells. 
Working hypothesis: VAT will induce more proliferation as compared to SQA, and 
tissues from obese mice will have increased proliferative activity as compared to lean 
mice. 
 
Specific Aim 2 
To measure the pro-proliferative activity of VAT and SQA and PPA tissue secretions on 
PC-3 PCa cells. 
Working hypothesis: PPA tissue induces more proliferation as compared to that of other 
adipose depots tested.  
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In the present study, I first analyzed the effect of obesity on pro-proliferative activity of 
VAT compared to the SQA tissue of lean and obese mice on human dermal 
microvascular endothelia cells (HMVEC). In the next part of the experiment, I compared 
the effect of SQA, VAT, and PPA tissue secretions on PCa cell line PC-3. The results 
from this research in vitro will show us if the PPA secretions cause more proliferation in 
PC-3 cells compared to other adipose depots.  
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MATERIALS AND METHODS 
 
Adipose tissue harvests 
Two strains of mice, wildtype (WT) C57Bl/6J and obese (ob/ob) mice, B6.Cg-
Lepob/J, were used for this study. For the first aim, two experiments were performed, the 
first using three mice per group at 6 months of age and the second using five mice per 
group  at 6 months of age.  The adipose tissue secretion samples from the second group 
of mice were used in the second aim.  The second aim used an additional 7 mice in   at 4 
months of age. Mice were housed in the Animal Research Center (ARC). Mice were 
either obtained from current colonies (WT) or were purchased from Jackson 
Laboratories. Mice were fed a regular chow diet ad libitum (Teklad 7912) until they 
reached 4 or 6 months of age. Tissue harvests were conducted in the necropsy room in 
the ARC. Mice were fasted for 4-6 hours before the tissue harvest. Mice were weighed 
and data was recorded. The mice were then euthanized by 1-3% isoflurane inhalation in a 
desiccator jar followed by cervical dislocation. For cervical dislocation, the back end of a 
tweezers was pushed down and forward on the back of the neck of the animal at the base 
of the head. The tail was pulled by the other hand backward at 30ºC to the surface of the 
table for dislocation. No heartbeat was felt before a surgical cut was made. A midline 
incision through the abdominal skin was then performed. The SQA adipose tissues were 
harvested from both sides of animal’s body (near the fore- and hind-limbs) under the 
skin. A midline incision was made through the peritoneal lining. The visceral fat pads in 
the abdomen were collected, and then the intestinal organs were moved aside to reveal 
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the prostate.  The PPA tissue, which covers the prostate organ, was then dissected and 
collected.  VAT, SQA, and PPA tissues were placed on ice in a 50 ml conical tube on ice 
and transferred to the lab for processing. 
All procedures were approved by the University of Wisconsin Milwaukee Institutional 
Animal Care and Use Committee.  
 
Adipose tissues explant cultures and conditioned media collection 
Harvested tissues were immediately processed in the lab for explant cultures. Adipose 
tissues were first weighed, and then washed twice in sterile Dulbecco’s phosphate 
buffered saline (PBS) in a tissue culture hood. Tissues were processed using sterile 
instruments. Tissues were minced into 0.5 mm pieces using scissors, and tweezers were 
used to place the minced adipose tissue pieces into a 10 cm or smaller cell culture dish. 
Five ml of serum-free Dulbecco’s Modified Eagle Medium (DMEM) containing 1% 
penicillin/streptomycin (P/S) was added to each dish. Serum free conditioned media 
(CM) were then collected after 48 hours of incubation and stored at 4ºC until use in MTT 
assays. 
 
HMVEC and PC-3 PCa cell culture  
Human dermal microvascular endothelial cells are a normal human endothelial cell strain, 
(HMVEC-d; Lonza). The cells were grown in endothelial growth medium (EBM-2) 
containing 10% fetal bovine serum (FBS) and the bullet kit in pre 0.01% gelatinized T75 
flasks. The flasks containing cells then were incubated at 37°C with 5% CO2. 
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PC-3 is a PCa cell line derived from a human bone metastasis (Kaighn et al., 1979). 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 1% P/S (Sigma Aldrich) was used as a growth media to maintain PC-3 
cells, which were grown at 37°C with 5% CO2.   
 
Proliferation assays 
For the proliferation assay, cells were plated in 96 well plates (Corning Inc.). To enhance 
cell adherence to the surface of the 96-well plates, they were gelatinized with 0.01% 
gelatin (Difco TM Gelatin) overnight. The HMVECs were harvested and counted using a 
hemocytometer or a cellometer (Nexcelom). The HMVECs were then re-suspended at a 
concentration of 20,000 cells/cm². The growth surface of a 96 well plate was 0.32 
cm²/well with a 0.2 ml volume; therefore, 32,000 cells/well were used. The HMVECs 
were then plated into a 0.01% gelatinized 96 well plate, that was prewashed with 200 µL 
PBS using a multichannel pipette. The plate was then incubated at 37°C with 5% CO2 for 
24 hours. The growth media were changed after the overnight incubation. The media 
were aspirated from each well and cells were gently washed with 200 µl per well of PBS. 
After aspirating the PBS, the cells were then treated with 100 µl per well basal EMB-2 
media (serum free media) and incubated for four hours. This starvation step was 
performed to synchronize cells in the cell cycle. Meanwhile, the treatment samples (CM 
from each adipose tissue type with or without PBS) were prepared on ice at 30, 50, and 
100% concentration of CM or at 1-50µg/ml for concentrated media. After 4 hours, the 
basal media was aspirated and the treatment samples were added to the appropriate wells. 
Samples were tested in duplicate for most samples. Growth media and basal media were 
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added each to three wells, as positive and negative controls, respectively. The plate was 
then incubated for four days. The plate was checked every day for any contamination. For 
the methylthiazol tetrazolium (MTT) assay, the treatment media was aspirated, and the 
HMVECS were labeled by adding 100 µL of fresh serum-free culture medium plus 10 µL 
of the 12 mM MTT stock solution was added to each well and the plate incubated at 37°C 
for 4 hours. After this labeling process, the medium, except for 25 µL, were removed 
from the wells and 50 µL of dimethyl sulfoxide (DMSO) was added to each well and 
mixed thoroughly with a pipette. After incubating at 37°C for 10 minutes, the plate was 
read at 540 nm absorbance on the BIO-Tek Synergy HT plate reader. The absorbance 
data for each sample was entered into an excel spreadsheet. Each test sample was 
normalized by dividing the absorbance by the gram weight of the corresponding tissue 
sample.  Normalized data was entered into the Sigma plot program and the mean values 
were graphed.  
 
The same proliferation assay was also performed for the PC-3 cells. However, in this 
assay, DMEM growth media or DMEM basal media were used to treat these cells. The 
concentration of 16,000 cells/ well (20,000 cells/ cm2) was used to plate PC-3 cells into a 
0.01% gelatinized 96 well plate.  
 
Lipolysis Assay 
Lipolytic activity of conditioned media of each of the three adipose tissue type was 
performed via the free glycerol assay (Sigma Aldrich, Saint Louis MO, F6428). The rate 
of breakdown of triglycerides to a glycerol and three free fatty acids directly indicated the 
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level of lipolysis. Briefly, 800 µL of free glycerol reagent (Sigma F6428) was added to 
all the standards (Sigma G7793) and the sample cuvettes. Ten microliter of each standard 
was then added to the standards cuvette. 100 µL of each sample conditioned media was 
also added to the sample cuvettes. The samples and standards were mixed thoroughly 
with a pipette. Ten microliter of mQH2O was also added to two empty cuvettes to be used 
as the reagent blanks. The absorbance was read at 540 nm using a spectrophotometer. 
The standard curve was performed using the glycerol standard (Sigma Cat# 03008), and 
the each sample lipolytic activity was then measured and compared with the standard 
curve. The free glycerol data were then normalized to the total cell number.  
 
Concentration of CM 
After collecting the conditioned media from each adipose tissue type (VAT, SQA, and 
PPA tissue) into a 15 or 50 ml conical tube, the samples were centrifuged at 2500 rpm at 
4 °C for 10 minutes to remove any residual cells. The cell free supernatants were 
concentrated 5 fold using Millipore Ultra-free membrane (Amicon Ultra, Billerica, MA). 
Briefly, the membrane was wet with 5-10 ml of sterile PBS and centrifuged at 2000 x g at 
4°C for 10 minutes. Approximately 10 ml of the conditioned media was then added into 
the filter unit, and it was centrifuged again at 2000 x g at 4°C for 30-60 minutes. The 
filtrate was discarded every 5-10 minutes. All the conditioned media were added to the 
membrane and washed with 1-2 volumes of PBS. When the phenol red color of the media 
had cleared, the media were centrifuged to concentrate the sample 10 fold compared with 
the original media volume. The conditioned media were then collected in a siliconized 
microfuge tube to eliminate any protein attachment to the tube wall. 
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Protein quantification of CM 
The Coomassie dye binding assay was used to detect and quantify the total protein in 
samples. The Thermo-Pierce protocol was used to perform this assay. Briefly, about 10 
ml of the Coomassie protein assay reagent, which is a dye, was aliquoted into a 15 ml 
conical tube. 490 µl of the dye was then added to pre-labeled microfuge tube for both 
samples and the standards. 10 µl of PBS then was added to the first standard tube and 10 
µl of each standard was also added to the rest of the standard tubes based on the 
concentration respectively and mixed with the dye. Specific amount of total protein was 
calculated for each sample. 10 µl of each sample was added to the labeled microfuge 
tube. The color of the solution in the tubes was compared to the standards to assure the 
sample was within the range of the standard curve. If the color of any sample was darker 
than the standards, they were diluted with the autoclaved water. 225 µl of each sample 
and standard were then added to each well of a 96 well plate in duplicate. Finally, the 
plate reader (BioTek, Synergy HT) was used to read the plate at 595 nm. The KC-4 
program produced the standard curve based on the standards and the mean concentrations 
of the samples. 
 
STATISTICAL ANALYSIS 
Student t-tests was used to compare the HMVEC and PCa cell proliferation induced by 
VAT, SQA, and PPA tissue secretions at each dose.  In addition, each of these groups 
was compared between lean and obese tissues. Within in a tissue, a dose response of the 
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samples was assessed by analysis of variance (ANOVA). P-value ≤ 0.05 was considered 
statistically significant.  
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RESULTS 
 
Concentrated adipose conditioned media (CM) did not induce proliferation of a 
human normal endothelial cell lines. 
Direct direct effect of secretions from adipose tissues on PCa cells or endothelial 
cells has not been well studied, therefore, to evaluate the pro-angiogenic effects of obese 
adipose tissue on human normal endothelial cells, and to investigate if VAT has more of 
a pro-proliferative effect on these cells as compared to SQA tissue, I first treated 
HMVEC cells with either lean or obese concentrated VAT and SQA tissue CM at 1 – 50 
µg/ml for five days and measured proliferation using an MTT assay.  
 
In my initial experiment, I tested 10 and 50 µg/ml total protein. As seen in Figure 1a and 
1c, not only did the samples not induce proliferation, at the 50 µg/ml dose, the CM 
slightly inhibited proliferation in both the wildtype and obese mice samples and in both 
the SQA and visceral fat pad (VFP) tissue samples CM (P-value ≤ 0.01). Therefore, I 
reduced the concentration of the CM to 1 and 5 µg/ml, and tested HMVEC proliferation 
again as above. With these doses, again, no pro-proliferative activity was observed 
(Figure 1b,d), and the obese SQA CM, at the 5 µg/ml dose, slightly inhibited 
proliferation (Figure 1b) (P-value ≤ 0.003). 
  
 
24 
 
 
 
Figure 1. Concentrated adipose tissue serum-free conditioned media (CM) did not induce 
proliferation of human microvascular endothelial cells (HMVEC). Adipose tissue explant culture CM 
were collected from (a,b) subcutaneous (SQA) or (c,d) abdominal visceral fat pad (VFP) tissues from 
wildtype or obese mice (n=3 per group) and concentrated 10 fold. The concentrated CM were tested on 
HMVEC at different dosages [50, 10 (a,c), 5 and 1 (b,d) µg/ml] for 5 days, then an MTT assay was 
performed. In (a) WT SQA 50 µg/ml; +P-value ≤ 0.01 vs. the negative control. In (b) obese SQA 5 µg/ml; 
*P-value ≤ 0.003 vs. WT SQA 5 µg/ml. In (c) WT VFP 50 µg/ml; +P-value ≤ 0.001 vs. the negative 
control. In (c) obese VFP 50 µg/ml; +P-value ≤ 0.004 vs. the negative control. In (d) there was no 
significant result. 
 
 
Unconcentrated visceral fat pad (VFP) conditioned media (CM) from lean mice 
induced proliferation of human microvascular endothelial cells. 
In the initial experiments, with concentrated CM, I did not observe any proliferation in 
the HMVEC cells. While analyzing these results, one difference that I noted between my 
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 study and the Venkatasubramanian study (Venkatasubramanian et al., 2014), was that 
the authors used unconcentrated CM from the human adipose tissue samples in that 
study. Therefore, I tested the proliferation of HMVECs using un-concentrated CM of 
each adipose tissue type of lean (wildtype) mice at three different dosages, 30%, 50%, 
and 100% CM. As shown in figure 2, the VFP from WT mice at 100% significantly 
induced proliferation as compared to the negative control and to the SQA CM at 100% 
(P-value < 0.001, n=5).  At the lower doses of VFP (30, 50%) and the 50% dose of SQA,  
there was statistically significant inhibition of HMVEC proliferation; SQA (Figure 2; P-
value< 0.001), VFP at the 30% dose (P-value ≤ 0.02), and VFP 50% (P-value ≤ 0.001) 
(Figure 2). We showed that wildtype VAT secretions have the ability to induce HMVECs 
at high dose when it is not concentrated, but at lower doses, appeared to inhibit the 
proliferation. These data confirmed the effect of visceral adipose tissue on cell 
proliferation.  
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Figure 2. Unconcentrated visceral fat pad (VFP) conditioned media (CM) from lean mice induced 
proliferation of human microvascular endothelial cells. HMVEC cells were treated with unconcentrated 
VFP or subcutaneous adipose (SQA) tissue CM from wildtype or obese mice at different dosages (30%, 
50%, and 100%; n=5 per group). An MTT assay was performed on day 5. There was a significant 
proliferation from VFP 100% *P-value < 0.001 vs. SQA 100% and the negative control. There was 
significant inhibition from SQA 50%; +P-value ≤ 0.001, VFP 30%; +P-value ≤ 0.02, and VFP 50%; +P-
value ≤ 0.001 vs. the negative control. 
 
Unconcentrated subcutaneous adipose (SQA) tissue conditioned media (CM) 
induced human PCa cell line, PC-3, proliferation cells at 30% dilution but not at full 
concentration. 
As angiogenesis is just one mechanism of pro-tumorigenic activity of the adipose tissue 
secretions, I also tested their effects on PC-3 PCa cells. I plated the PC-3 cells at 
concentration of 16,000 cells/ well and treated them with the same VAT and SQA tissue 
secretions as used previously on the HMVECs (30%, 50% and 100%) for five days. I 
assessed proliferation using an MTT assay as above.  While most samples were analyzed 
in duplication, for some samples, there was only enough CM to run in in a single well.  
However, a total of 5 mice were analyzed per group. As seen in figure 3, only SQA at the 
30% dose induced PC-3 cell proliferation significantly as compared to the negative 
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control (Figure 3; P-value ≤ 0.05). No other concentration in the SQA CM or any of the 
VFP samples had a significant effect (Figure 3).  
 
Figure 3. Unconcentrated subcutaneous adipose (SQA) tissue conditioned media (CM) induced 
human PC-3 prostate cancer cell proliferation only at 30% dilution. The PC-3 cells were treated with 
unconcentrated subcutaneous adipose (SQA) tissue or VFP CM from wildtype (lean) mice at different 
dosages (30%, 50%, and 100%; n=5 per group). An MTT assay was performed on day 5. Most samples 
were run in duplicate; however, the CM from some mice had only enough CM to run in a single well. 
However, multiple mice were included in each group. The significant proliferation was seen from SQA 
30% *P-value <0.05 vs. the negative control. 
 
Unconcentrated periprostatic adipose (PPA) tissue CM from lean mice induced 
human prostate cancer cell line, PC-3 cells.  
The previous study by Venkatasubramanian et al. have demonstrated that both 
endothelial and PCa cell proliferation were significantly induced when they were treated 
with obese human PPA tissue secretions (Venkatasubramanian et al., 2014). In mice, very 
little PPA tissue can be obtained. However, based on the discrepancy between my 
analysis of VFP and the human study, I collected PPA and compared it to the effects of 
both SQA and the VFP tissue secretions.  PC-3 cells were plated as above, and then 
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treated with doses of 30%, 50%, and 100% CM issue type secretions for five days. An 
MTT proliferation assay was then performed. In this experiment, when raw data were 
analyzed only the SQA tissue CM at 30% induced PC-3 cell proliferation significantly 
(Figure 4; P-value < 0.04, n=2). 
 
Figure 4. Unconcentrated SQA tissue conditioned media from lean mice induced human prostate 
cancer cell line, PC-3 cells at 30% concentration (4 months old mice, n=2 mice). The previous 
experiment was repeated, the only significant cause of PC-3 cells proliferation was SQA 30%; *P-value < 
0.04 vs. the negative control. Significant differences in proliferation of PC-3 cells were also observed from 
SQA 30%; P-value ≤ 0.001 vs. VFP 30%. Also, SQA 30%; P-value ≤ 0.01 vs. PPA 30%. The VFP 30% 
was also significant as compared to the PPA 30% (P-value ≤ 0.01). 
 
 
PC-3 cells were treated with conditioned media from five more wildtype mice, but 
no significant proliferation was seen.  
The same experiment was repeated testing a larger sample size to achieve a more 
accurate result. The PC-3 cells were plated and treated the same way as mentioned above. 
No significant induction was observed in PC-3 cell proliferation after treating them with 
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the three doses of each adipose tissue types. Nevertheless, inhibition was observed in PC-
3 cells treated with VFP 50% (Figure 5; P-value ≤ 0.04), PPA 50% and 100% (P-value ≤ 
0.02) as compared to the negative control (Figure 5). 
Based on figure 4 and 5, despite the study by Venkatasubramanian et al. my study did not 
show any proliferation of PC-3 cells by any adipose tissue type CM except SQA 30%. As 
the amount of tissue collected between depots varies, with PPA being the least amount of 
tissue, I normalized the proliferation data per total protein content in the CM samples. 
 
 
 
Figure 5. The same experiment was performed from different adipose tissues CM of 5 mice on PC-3 
cells. The result indicated a significant Inhibition of PC-3 cells from PPA 50%; +P-value < 0.02 vs. the 
negative control. PPA 100%; +P-value <0.02 vs. the negative control. VFP 50%; +P-value ≤ 0.04 vs. the 
negative control. Significant inhibition was also seen from VFP 100%; P-value ≤ 0.05 vs. PPA 100%. 
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The wildtype PPA unconcentrated conditioned media induced proliferation of 
human PC-3 prostate cancer cells.  
In order to determine the amount of total protein content in the CM samples, a Coomassie 
dye binding assay was performed for all seven mice that we had tested their adipose 
tissue secretions on PC-3 cells previously. The MTT proliferation assay data was then 
normalized to total protein concentration of each sample and graphed. Significant 
induction in PCa proliferation was observed via PPA CM at all three doses of 30, 50, and 
100%. This induction was more than two fold than either SQA or VFP samples (Figure 6; 
P-value < 0.001, n=7). 
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Figure 6. Normalized results of unconcentrated conditioned media (CM) demonstrate that 
periprostate adipose (PPA) tissues induced proliferation of human PC-3 prostate cancer cells. The 
PC-3 cells were treated with unconcentrated adipose tissue CM from wildtype mice or obese mice (n=7 per 
group) at different dosages (30%, 50%, and 100%) for 5 days, then the MTT assay was performed. Total 
protein concentration of each sample was obtained via a Coomassie dye binding assay. The MTT data was 
normalized to total protein concentration for each sample and graphed. *P-value <0.001. 
 
 
There were no significant differences between lipid catabolic rates of each adipose 
tissue. 
Free glycerol levels of SQA, VFP, and PPA tissue CM of five wildtype mice were 
measured via a lipolysis assay. The glycerol values were then normalized to gram weight 
of each adipose tissue sample. No differences in lipolytic rates were observed between 
the adipose tissue depots (Figure 7). 
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Figure 7. There were no significant differences between lipid catabolic rate of each adipose tissue.  
Lipolysis, the rate of triglyceride breakdown, was measured for each adipose tissue depot using a free 
glycerol assay.  The glycerol values were then normalized to gram weight of each adipose tissue sample. 
No significant differences in lipolytic rates were observed between the tissue depots. 
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DISCUSSION  
 
Several studies demonstrate that visceral obesity is directly associated with 
aggressive PCa (Kane et al., 2005; Mistry et al., 2007). Some proteins including; leptin, 
IL-6, and TNF-α are produced by adipose tissues, and higher amounts of these substances 
are produced with obesity (Fonseca-Alaniz et al., 2007), when the size and number of the 
adipocytes increases.  Several studies have linked PCa aggressiveness to the higher 
production of these cytokines and hormones via obese adipose tissues (Mistry et al., 
2007). Recent research has shown that increases thickness of PPA tissue positively 
correlates with PCa aggressiveness (Bhindi et al., 2012) and that the PPA secretes high 
levels of IL-6 (Finley et al., 2009). In addition, one study has shown that human PPA 
secretions induce proliferation of both PCa cells and of endothelial cells 
(Venkatasubramanian et al., 2014). The goal of this study was to determine if PPA tissue 
secretions from a mouse model induce pro-proliferative activity in PCa cells and 
microvascular endothelial cells as compared to the abdominal visceral adipose tissue or 
subcutaneous adipose tissue.  
Specific Aim 1 
To quantify the pro-proliferative activity of subcutaneous (SQA) and visceral adipose 
tissue (VAT) secretions on normal human endothelial cells. 
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Working hypothesis: VAT will induce more proliferation as compared to SQA, and 
tissues from obese mice will have increased proliferative activity as compared to lean 
mice. 
In my initial experiment, I treated normal human microvascular endothelial cells with 
either VAT or SQA tissue secretions. This experiment was performed for multiple 
reasons. First, I needed to determine if mouse adipose tissue CM could induce 
proliferation in human cells.  Secondly, I specifically wanted to determine if the 
secretions from either tissue were pro-angiogenic. Thirdly, I wanted to establish if this 
angiogenic activity differed between adipose depots, SQA versus VAT secretions.  
Lastly, I aimed to establish a dose range for this activity and subsequent experiments.  In 
the first experiment, concentrated CM (10-fold) was used. I tested a range of doses from 
1 to 50 µg/ml of the CM. The result indicated that the doses of 10 and 50 µg/ml of the 
CM actually inhibited HMVECr proliferation, rather than induce it. The same experiment 
was then performed using 1 and 5 µg/ml, and again, there was no significant increase in 
proliferation at these lower doses. These data are not consistent with the study by 
Venkatasubramanian et al study, which showed that, CM from lean patients did induce 
proliferation of HMVECs above that of basal media. One difference between these 
studies is that I used visceral fat pad secretions while Venkatasubramanian et al. (2014) 
specifically used PPA tissue, which is a subtype of VAT.  Another difference is that they 
used unconcentrated serum free CM in their study. Thus, it was possible that 
concentrating the CM might affect the CM activity as there maybe bioactive factors in 
unconcentrated CM that are destroyed or weakened during concentration or it may 
concentrate an inhibitory factor.  
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Therefore, in the next part of the study, I collected additional samples and assessed 
HMVEC proliferation using unconcentrated CM. Each CM was used undiluted (100% 
dose) or diluted with basal media to achieve the doses of 30% or 50% dilutions to obtain 
a dose response. In contrast to the first part of the study, a significant induction of 
proliferation was seen in the undiluted (100%) VAT secretions. This observation is 
consistent with that of Venkatasubramanian et al. (2014), and it supports the hypothesis 
that visceral adipose tissue secretions are more pro-angiogenic than SQA tissue 
secretions. This increased pro-angiogenic activity may be due to differences in the 
expression level of adipokines in these different adipose depots (Greenberg and obin, 
2006). For example the expression level of IL-6 is higher from VAT than SQA tissue 
(Gustafson, 2010), and IL-6 is an established pro-angiogenic factor (Lazar-Molnar et al., 
2000 and Wani et al., 2011). Thus, based on my observations and the results of reported 
studies, it is possible that the increased angiogenic activity I observed in the VAT 
samples is due to the high levels of IL-6 produced by this tissue.  Future studies will be 
needed to specifically test this hypothesis. In addition, future studies should also compare 
tissues from lean versus obese mouse models to determine if VAT tissues from obese 
mice are more pro-angiogenic as compared to lean mouse tissues, as was shown for 
human tissues (Venkatasubramanian et al. 2014). 
 
Specific Aim 2 
To measure the pro-proliferative activity of VAT and SQA and PPA tissue secretions on 
PC-3 PCa cells. 
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Working hypothesis: PPA tissue induces more proliferation as compared to that of other 
adipose depots tested. 
 
In the next part of the study, I treated human PC-3 PCa cells with the unconcentrated 
SQA tissue and VAT CM collected above.  In this initial assay, CM of SQA tissue at the 
30% dilution enhanced the proliferation of PC-3 cells significantly as compared to 
untreated cells. This was also significant as compared to the CM of VAT at the 30% 
dilution.  However, the VAT secretions did not induce PC-3 cell proliferation as 
expected. I expected this result based on the Venkatasubramian et al. study where human 
VAT induced PC-3 cell proliferation (Venkatasubramian et al., 2014). However, in the 
Venkatasubramian et al. study, the authors specifically tested PPA tissue as the visceral 
adipose tissue source (Venkatasubramian et al., 2014). In my initial study, I used the 
visceral fat pad as the visceral adipose tissue source. Thus, I hypothesized that the locale 
that the visceral adipose tissue was taken was a key factor in activity level.  
 
Although it is difficult to collect PPA from mice, and very little tissue can be obtained, to 
determine if PPA tissue is distinct from the abdominal VAT, I collected PPA, VAT, and 
SQA tissue from additional mice.  I treated PC-3 PCa cells with unconcentrated SQA, 
VAT, and PPA tissue CM collected from five mice at three doses, 30%, 50%, and 100%. 
The raw data showed no increase in proliferation over that of the basal media, and in fact 
showed a decrease in cell number with   the PPA secretions   as compared to the negative 
control.  This was not consistent with the published study on human tissues 
(Venkatasubramian et al, 2014).  However, I also noted that in this study, they 
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normalized the pro-proliferative activity.  Therefore, it seemed appropriate to normalize 
the data in my study to provide a more precise means of comparison between the tissues.  
Therefore, I normalized the proliferation data per total protein content in the CM samples 
per gram weight of tissue, both standard measures by which data are normalized. The 
graphed normalized data revealed that, per µg total protein, the PPA tissues secretions 
induced higher cell numbers as compared to the VAT or SQA tissue secretions. This 
proliferation from PPA tissue was more than two fold higher as compared to other 
adipose depots. These data are consistent with the Venkatasubramanian et al. study which 
showed that CM from PPA from lean PCa patients induced proliferation of PC-3 cells 
(Venkatasubramanian et al., 2014).   
 
My study is the first to confirm the Venkatasubramian findings in a mouse model.  While 
these data show that PPA tissue secretions support a pro-proliferative microenvironment, 
they do not delineate a mechanism of this activity. In a study by Finely et al., the authors 
showed that the PPA tissue produced high levels of IL-6 and this level correlated with 
high tumor grade (Finely et al., 2009). Moreover, Riberio et al. indicated that PCa 
provides a favorable microenvironment for PPA tissue to become metabolically more 
active. This cellular crosstalk between tumor cells and the PPA tissue cells stimulates and 
increases the secretion level of some adipokines, such as IL-6 and TNF-α which lead to 
PCa aggressiveness (Ribeiro et al., 2012). In another study, the level of pro-MMP-9 was 
reported to be higher in PPA tissue sample from PCa patients as compared to that of 
benign prostate hyperplasia (Sacca et al., 2012a), and increased MMP-9 has been 
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implicated in PCa metastasis (Johnson et al., 2010). Therefore, these characteristics of the 
PPA tissue may explain the results of my experiments.  
 
Another mechanism that could be involved in tumor progression is increased fatty acid 
availability. Obese adipose tissue is known to secrete higher levels of fatty acids (de 
Ferranti and Mozaffarian, 2008). For example, elevated level of IL-6 was shown to 
induce lipolysis in VAT, which increases the release of FFA (Pradhan et al., 2001). 
Higher production of FFA is directly associated with insulin resistance (Boden G, 2011). 
Insulin is a key regulator of growth (Hsu et al., 2007); therefore, a higher amount of 
insulin due to insulin resistance could increase PCa cell proliferation. Moreover, high 
level of insulin can lead to activation of some growth hormones, including insulin-like 
growth factor (IGF) (Friedrich et al., 2012). IGF is known to have a mitogenic effect 
(Frasca et al., 1999; Hsu et al., 2007). Hence, these cellular mechanisms could enhance 
proliferation of some cancer cells. For example, an epidemiologic study by Manousos et 
al. demonstrated that there is direct link between serum IGF-1 and IGF-II and colorectal 
cancer (Manousos et al., 1999). The IGF-I can also increase the level of vascular 
endothelial growth factor (VEGF) which leads to angiogenesis (Fukuda et al., 2002; 
Stearns et al., 2005). Thus, increased levels of FFA from the PPA could contribute to PCa 
progression.  
 
Therefore, in the last part of my research, I measured the lipolytic activity of each 
adipose tissue depot. The lipolysis assay was performed as a measure of the level of FFA 
produced from triglycerides by each adipose tissue type. Since in a human subjects study 
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the rate of lipolysis was reported to be higher in VAT than SQA tissue (Jensen, 2006), I 
expected to observe a higher lipolytic activity from the VAT and PPA tissues as 
compared to the SQA tissues. However, no significant differences were observed 
between the mean value of the SQA, VAT, and PPA tissue’s lipolytic activity. One likely 
explanation for this difference might be related to the nature of the models. Smaller 
amount of adipose tissue can be collected from mice than human. Jensen used human 
subjects, while I used mouse tissues.   
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CONCLUSION 
The role of secretions from three adipose tissue types, including SQA, VAT, and 
PPA were compared for pro-proliferative activity on human PCa cell line PC-3. It was 
hypothesized that secretions from VAT, and PPA tissue, a subtype of VAT, have a 
promoting effect on PCa progression as compared to that of abdominal VAT or SQA 
tissue secretions. For the first specific aim, the effect of abdominal VAT and SQA tissue 
secretions from lean mice on HMVEC was tested. The proliferation result from these 
samples at different concentrations did not indicate any significant proliferation of 
HMVECs. However, unconcentrated CM from the VAT at the 100% dose significantly 
induced HMVEC proliferation.  
 
Specific aim 2 was focused on pro-proliferative activity of SQA, VAT, and PPA tissue 
secretions on PC-3 cells. The normalized proliferation data showed that the PPA tissue 
secretions at all three doses produced higher cell numbers, two-fold higher, as compared 
to the SQA and VAT secretions.  Finally the lipolytic activity of SQA, VAT, and PPA 
tissue was measured, but no significant difference was seen between the FFA levels of 
these three adipose depots. In summary, my data supported my hypothesis that PPA 
tissue from a mouse model had similar characteristics to that taken from human tissues in 
that it induced pro-proliferative activity of PCa cells.   
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